Roche labs by Ray Sahelian, M.D.

November 2006 - U.S. Food and Drug Administration staff have recommended adding a new precaution to the label of Roche AG's flu-fighting drug Tamiflu about reports of psychiatric problems in patients who take it. The FDA reviewers said they evaluated 103 reports of delirium, suicidal behavior and other mental problems from August 2005 to July 2006. Three cases were fatal. Nearly all of the cases, 95 out of 103, came from Japan.

Roche Laboratories Inc., is the maker of Accutane.